UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

Jean Bousquet; Boleslaw Samolinski; Igor Kaidashev; Marcus Maurer; Nicolas Roche; Bernardo Sousa-Pinto; Andrii Kurchenko; Roman Stepanenko; Vladyslav Tsaryk; Ludger Klimek; Maria Teresa Ventura; Anna Bedbrook; Wienczyslawa Czarlewski; Yuliia Lysanets; Maciej Kupczyk; Łukasz Skolimowski; Marek Kulus; Stefano Del Giacco; Markus Ollert; Judith Garcia-Aymerich; Carlos Robalo Cordeiro; Arzu Yorgancioglu; Christoph Schlapbach; Rita Amaral; Cristina Bonaglia; Isabelle Bossé; Rosalba Buquicchio; Demetrios Christou; Galyna Fedoruk; Pietro Fontanesi; Bilun Gemicioglu; Antonio F.M. Giuliano; Paolo Lepore; Alla Nakonechna; Sophia Neisinger; Ana M. Pereira; Aiste Ramanauskaite; Filip Raciborski; Brigita Sitkauskiene; Oksana Sokhatska; Viktor Stepanenko; Katarina Stevanovic; Orysya Syzon; Violeta Kvedariene; Govert de Vries; Michiel van Eerd; Arunas Valiulis; Joao A. Fonseca; Josep M. Anto; Tari Haahtela; Holger Schünemann; Torsten Zuberbier

doi:10.1111/all.15855

UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

Jean Bousquet^*, Boleslaw Samolinski, Igor Kaidashev, Marcus Maurer, Nicolas Roche, Bernardo Sousa-Pinto, Andrii Kurchenko, Roman Stepanenko, Vladyslav Tsaryk, Ludger Klimek, Maria Teresa Ventura, Anna Bedbrook, Wienczyslawa Czarlewski, Yuliia Lysanets, Maciej Kupczyk, Łukasz Skolimowski, Marek Kulus, Stefano Del Giacco, Markus Ollert, Judith Garcia-AymerichCarlos Robalo Cordeiro, Arzu Yorgancioglu, Christoph Schlapbach, Rita Amaral, Cristina Bonaglia, Isabelle Bossé, Rosalba Buquicchio, Demetrios Christou, Galyna Fedoruk, Pietro Fontanesi, Bilun Gemicioglu, Antonio F.M. Giuliano, Paolo Lepore, Alla Nakonechna, Sophia Neisinger, Ana M. Pereira, Aiste Ramanauskaite, Filip Raciborski, Brigita Sitkauskiene, Oksana Sokhatska, Viktor Stepanenko, Katarina Stevanovic, Orysya Syzon, Violeta Kvedariene, Govert de Vries, Michiel van Eerd, Arunas Valiulis, Joao A. Fonseca, Josep M. Anto, Tari Haahtela, Holger Schünemann, Torsten Zuberbier

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

8 Citations (Scopus)

Abstract

Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK-air® (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE® (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK-air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician's computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician's web browser. UCRAID—developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)—is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies.

Original language	English
Pages (from-to)	2581-2595
Number of pages	15
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	78
Issue number	10
Early online date	28 Aug 2023
DOIs	https://doi.org/10.1111/all.15855
Publication status	Published - Oct 2023

Keywords

asthma
mHealth
rhinitis
Ukrainian refugees
urticaria

Access to Document

10.1111/all.15855Licence: CC BY-NC

Cite this

Bousquet, J., Samolinski, B., Kaidashev, I., Maurer, M., Roche, N., Sousa-Pinto, B., Kurchenko, A., Stepanenko, R., Tsaryk, V., Klimek, L., Ventura, M. T., Bedbrook, A., Czarlewski, W., Lysanets, Y., Kupczyk, M., Skolimowski, Ł., Kulus, M., Del Giacco, S., Ollert, M., ... Zuberbier, T. (2023). UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan. Allergy: European Journal of Allergy and Clinical Immunology, 78(10), 2581-2595. https://doi.org/10.1111/all.15855

@article{4925cb8ec2a24495a12e797f87bc49be,

title = "UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan",

abstract = "Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK-air{\textregistered} (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE{\textregistered} (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK-air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician's computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician's web browser. UCRAID—developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)—is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies.",

keywords = "asthma, mHealth, rhinitis, Ukrainian refugees, urticaria",

author = "Jean Bousquet and Boleslaw Samolinski and Igor Kaidashev and Marcus Maurer and Nicolas Roche and Bernardo Sousa-Pinto and Andrii Kurchenko and Roman Stepanenko and Vladyslav Tsaryk and Ludger Klimek and Ventura, {Maria Teresa} and Anna Bedbrook and Wienczyslawa Czarlewski and Yuliia Lysanets and Maciej Kupczyk and {\L}ukasz Skolimowski and Marek Kulus and Stefano Del Giacco and Markus Ollert and Judith Garcia-Aymerich and Carlos Robalo Cordeiro and Arzu Yorgancioglu and Christoph Schlapbach and Rita Amaral and Cristina Bonaglia and Isabelle Boss{\'e} and Rosalba Buquicchio and Demetrios Christou and Galyna Fedoruk and Pietro Fontanesi and Bilun Gemicioglu and Giuliano, {Antonio F.M.} and Paolo Lepore and Alla Nakonechna and Sophia Neisinger and Pereira, {Ana M.} and Aiste Ramanauskaite and Filip Raciborski and Brigita Sitkauskiene and Oksana Sokhatska and Viktor Stepanenko and Katarina Stevanovic and Orysya Syzon and Violeta Kvedariene and {de Vries}, Govert and {van Eerd}, Michiel and Arunas Valiulis and Fonseca, {Joao A.} and Anto, {Josep M.} and Tari Haahtela and Holger Sch{\"u}nemann and Torsten Zuberbier",

note = "Funding Information: MASK‐air SAS, CRUSE and MOXIE provided financial support for the UCRAID project. Funding Information: JB reports personal fees from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi‐Aventis, Teva, Uriach, other from KYomed‐Innov, other from Mask‐air‐SAS, outside the submitted work. TH reports personal fees from Orion Pharma, outside the submitted work. MM reports grants from Allakos, personal fees from Alvotech, grants and personal fees from Amgen, personal fees from Aquestive, personal fees from Aralez, grants and personal fees from AstraZeneca, personal fees from Bayer, grants and personal fees from Celldex, personal fees from Celltrion, grants and personal fees from Evommune, grants and personal fees from GSK, personal fees from Ipsen, grants from Kyowa Kirin, grants from Leo Pharma, grants and personal fees from Lilly, personal fees from Menarini, grants and personal fees from Mitsubishi Tanabe Pharma, grants and personal fees from Moxie, grants and personal fees from Noucor, grants and personal fees from Novartis, personal fees from Orion Biotechnology, personal fees from Resonance Medicine, grants and personal fees from Sanofi/Regeneron, personal fees from Septerna, grants and personal fees from Teva, personal fees from Trial Form Support International AB, grants and personal fees from Third HarmonicBio, grants and personal fees from ValenzaBio, grants and personal fees from Yuhan Corporation, personal fees from Zurabio, outside the submitted work. NR reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, grants and personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Zambon, personal fees from MSD, personal fees from Austral, outside the submitted work. VK reports non‐financial support from Norameda, non‐financial support from Dimuna, non‐financial support from Berlin Chemie Menarini, outside the submitted work. MK reports personal fees from Adamed, personal fees from Astra Zeneca, personal fees from Berlin Chemie, personal fees from Chiesi, personal fees from Emma, personal fees from GSK, personal fees from Novartis, personal fees from Sanofi, personal fees from Polfarma, personal fees from LEK‐AM, personal fees from Celon Pharma, personal fees from Zentiva, personal fees from HVD, outside the submitted work. BS reports personal fees from Polpharma, personal fees from Viatris, grants and personal fees from AstraZeneca, personal fees from TEVA, personal fees from patient ombudsman, personal fees from Polish Allergology Society, grants from GSK, outside the submitted work. TZ reports grants and personal fees from Novartis, grants and personal fees from Henkel, personal fees from Bayer, personal fees from FAES, personal fees from Astra Zeneca, personal fees from AbbVie, personal fees from ALK, personal fees from Almirall, personal fees from Astellas, personal fees from Bayer, personal fees from Bencard, personal fees from Berlin Chemie, personal fees from FAES, personal fees from Hal, personal fees from Leti, personal fees from Mesa, personal fees from Menarini, personal fees from Merck, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Sanofi, personal fees from Stallergenes, personal fees from Takeda, personal fees from Teva, personal fees from UCB, personal fees from Henkel, personal fees from Kryolan, personal fees from L'Oreal, outside the submitted work; and Organizational affiliations: Commitee member: WHO‐Initiative {\textquoteleft}Allergic Rhinitis and Its Impact on Asthma{\textquoteright} (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GALEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). CS reports personal fees from Abbvie, personal fees from Almirall, personal fees from BMS, personal fees from LEO Pharma, personal fees from Lilly, personal fees from Kiowa Kirin, personal fees from Novartis, personal fees from Pfizer, grants from PPM Services, outside the submitted work. The other authors have nothing to disclose, outside the submitted work. 2 Publisher Copyright: {\textcopyright} 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.",

year = "2023",

month = oct,

doi = "10.1111/all.15855",

language = "English",

volume = "78",

pages = "2581--2595",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "10",

}

Bousquet, J, Samolinski, B, Kaidashev, I, Maurer, M, Roche, N, Sousa-Pinto, B, Kurchenko, A, Stepanenko, R, Tsaryk, V, Klimek, L, Ventura, MT, Bedbrook, A, Czarlewski, W, Lysanets, Y, Kupczyk, M, Skolimowski, Ł, Kulus, M, Del Giacco, S, Ollert, M, Garcia-Aymerich, J, Robalo Cordeiro, C, Yorgancioglu, A, Schlapbach, C, Amaral, R, Bonaglia, C, Bossé, I, Buquicchio, R, Christou, D, Fedoruk, G, Fontanesi, P, Gemicioglu, B, Giuliano, AFM, Lepore, P, Nakonechna, A, Neisinger, S, Pereira, AM, Ramanauskaite, A, Raciborski, F, Sitkauskiene, B, Sokhatska, O, Stepanenko, V, Stevanovic, K, Syzon, O, Kvedariene, V, de Vries, G, van Eerd, M, Valiulis, A, Fonseca, JA, Anto, JM, Haahtela, T, Schünemann, H & Zuberbier, T 2023, 'UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan', Allergy: European Journal of Allergy and Clinical Immunology, vol. 78, no. 10, pp. 2581-2595. https://doi.org/10.1111/all.15855

UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan. / Bousquet, Jean; Samolinski, Boleslaw; Kaidashev, Igor et al.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 78, No. 10, 10.2023, p. 2581-2595.

Research output: Contribution to journal › Review article › peer-review

TY - JOUR

T1 - UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

AU - Bousquet, Jean

AU - Samolinski, Boleslaw

AU - Kaidashev, Igor

AU - Maurer, Marcus

AU - Roche, Nicolas

AU - Sousa-Pinto, Bernardo

AU - Kurchenko, Andrii

AU - Stepanenko, Roman

AU - Tsaryk, Vladyslav

AU - Klimek, Ludger

AU - Ventura, Maria Teresa

AU - Bedbrook, Anna

AU - Czarlewski, Wienczyslawa

AU - Lysanets, Yuliia

AU - Kupczyk, Maciej

AU - Skolimowski, Łukasz

AU - Kulus, Marek

AU - Del Giacco, Stefano

AU - Ollert, Markus

AU - Garcia-Aymerich, Judith

AU - Robalo Cordeiro, Carlos

AU - Yorgancioglu, Arzu

AU - Schlapbach, Christoph

AU - Amaral, Rita

AU - Bonaglia, Cristina

AU - Bossé, Isabelle

AU - Buquicchio, Rosalba

AU - Christou, Demetrios

AU - Fedoruk, Galyna

AU - Fontanesi, Pietro

AU - Gemicioglu, Bilun

AU - Giuliano, Antonio F.M.

AU - Lepore, Paolo

AU - Nakonechna, Alla

AU - Neisinger, Sophia

AU - Pereira, Ana M.

AU - Ramanauskaite, Aiste

AU - Raciborski, Filip

AU - Sitkauskiene, Brigita

AU - Sokhatska, Oksana

AU - Stepanenko, Viktor

AU - Stevanovic, Katarina

AU - Syzon, Orysya

AU - Kvedariene, Violeta

AU - de Vries, Govert

AU - van Eerd, Michiel

AU - Valiulis, Arunas

AU - Fonseca, Joao A.

AU - Anto, Josep M.

AU - Haahtela, Tari

AU - Schünemann, Holger

AU - Zuberbier, Torsten

N1 - Funding Information: MASK‐air SAS, CRUSE and MOXIE provided financial support for the UCRAID project. Funding Information: JB reports personal fees from Cipla, Menarini, Mylan, Novartis, Purina, Sanofi‐Aventis, Teva, Uriach, other from KYomed‐Innov, other from Mask‐air‐SAS, outside the submitted work. TH reports personal fees from Orion Pharma, outside the submitted work. MM reports grants from Allakos, personal fees from Alvotech, grants and personal fees from Amgen, personal fees from Aquestive, personal fees from Aralez, grants and personal fees from AstraZeneca, personal fees from Bayer, grants and personal fees from Celldex, personal fees from Celltrion, grants and personal fees from Evommune, grants and personal fees from GSK, personal fees from Ipsen, grants from Kyowa Kirin, grants from Leo Pharma, grants and personal fees from Lilly, personal fees from Menarini, grants and personal fees from Mitsubishi Tanabe Pharma, grants and personal fees from Moxie, grants and personal fees from Noucor, grants and personal fees from Novartis, personal fees from Orion Biotechnology, personal fees from Resonance Medicine, grants and personal fees from Sanofi/Regeneron, personal fees from Septerna, grants and personal fees from Teva, personal fees from Trial Form Support International AB, grants and personal fees from Third HarmonicBio, grants and personal fees from ValenzaBio, grants and personal fees from Yuhan Corporation, personal fees from Zurabio, outside the submitted work. NR reports grants and personal fees from Boehringer Ingelheim, grants and personal fees from Novartis, grants and personal fees from GSK, personal fees from AstraZeneca, personal fees from Chiesi, grants and personal fees from Pfizer, personal fees from Sanofi, personal fees from Zambon, personal fees from MSD, personal fees from Austral, outside the submitted work. VK reports non‐financial support from Norameda, non‐financial support from Dimuna, non‐financial support from Berlin Chemie Menarini, outside the submitted work. MK reports personal fees from Adamed, personal fees from Astra Zeneca, personal fees from Berlin Chemie, personal fees from Chiesi, personal fees from Emma, personal fees from GSK, personal fees from Novartis, personal fees from Sanofi, personal fees from Polfarma, personal fees from LEK‐AM, personal fees from Celon Pharma, personal fees from Zentiva, personal fees from HVD, outside the submitted work. BS reports personal fees from Polpharma, personal fees from Viatris, grants and personal fees from AstraZeneca, personal fees from TEVA, personal fees from patient ombudsman, personal fees from Polish Allergology Society, grants from GSK, outside the submitted work. TZ reports grants and personal fees from Novartis, grants and personal fees from Henkel, personal fees from Bayer, personal fees from FAES, personal fees from Astra Zeneca, personal fees from AbbVie, personal fees from ALK, personal fees from Almirall, personal fees from Astellas, personal fees from Bayer, personal fees from Bencard, personal fees from Berlin Chemie, personal fees from FAES, personal fees from Hal, personal fees from Leti, personal fees from Mesa, personal fees from Menarini, personal fees from Merck, personal fees from MSD, personal fees from Novartis, personal fees from Pfizer, personal fees from Sanofi, personal fees from Stallergenes, personal fees from Takeda, personal fees from Teva, personal fees from UCB, personal fees from Henkel, personal fees from Kryolan, personal fees from L'Oreal, outside the submitted work; and Organizational affiliations: Commitee member: WHO‐Initiative ‘Allergic Rhinitis and Its Impact on Asthma’ (ARIA); Member of the Board: German Society for Allergy and Clinical Immunology (DGAKI); Head: European Centre for Allergy Research Foundation (ECARF); President: Global Allergy and Asthma European Network (GALEN); Member: Committee on Allergy Diagnosis and Molecular Allergology, World Allergy Organization (WAO). CS reports personal fees from Abbvie, personal fees from Almirall, personal fees from BMS, personal fees from LEO Pharma, personal fees from Lilly, personal fees from Kiowa Kirin, personal fees from Novartis, personal fees from Pfizer, grants from PPM Services, outside the submitted work. The other authors have nothing to disclose, outside the submitted work. 2 Publisher Copyright: © 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.

PY - 2023/10

Y1 - 2023/10

N2 - Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK-air® (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE® (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK-air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician's computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician's web browser. UCRAID—developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)—is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies.

AB - Eight million Ukrainians have taken refuge in the European Union. Many have asthma and/or allergic rhinitis and/or urticaria, and around 100,000 may have a severe disease. Cultural and language barriers are a major obstacle to appropriate management. Two widely available mHealth apps, MASK-air® (Mobile Airways Sentinel NetworK) for the management of rhinitis and asthma and CRUSE® (Chronic Urticaria Self Evaluation) for patients with chronic spontaneous urticaria, were updated to include Ukrainian versions that make the documented information available to treating physicians in their own language. The Ukrainian patients fill in the questionnaires and daily symptom-medication scores for asthma, rhinitis (MASK-air) or urticaria (CRUSE) in Ukrainian. Then, following the GDPR, patients grant their physician access to the app by scanning a QR code displayed on the physician's computer enabling the physician to read the app contents in his/her own language. This service is available freely. It takes less than a minute to show patient data to the physician in the physician's web browser. UCRAID—developed by ARIA (Allergic Rhinitis and its Impact on Asthma) and UCARE (Urticaria Centers of Reference and Excellence)—is under the auspices of the Ukraine Ministry of Health as well as European (European Academy of Allergy and Clinical immunology, EAACI, European Respiratory Society, ERS, European Society of Dermatologic Research, ESDR) and national societies.

KW - asthma

KW - mHealth

KW - rhinitis

KW - Ukrainian refugees

KW - urticaria

UR - http://www.scopus.com/inward/record.url?scp=85168887034&partnerID=8YFLogxK

UR - https://pubmed.ncbi.nlm.nih.gov/37641384

U2 - 10.1111/all.15855

DO - 10.1111/all.15855

M3 - Review article

C2 - 37641384

SN - 0105-4538

VL - 78

SP - 2581

EP - 2595

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 10

ER -

UCRAID (Ukrainian Citizen and refugee electronic support in Respiratory diseases, Allergy, Immunology and Dermatology) action plan

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this